Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury.
A total of 66 spinal cord injury patients with erectile dysfunction entered a protocol of penile intracavernous pharmacotherapy with papaverine hydrochloride (30 mg. per ml.) or a combination of papaverine (25 mg. per ml.) and phentolamine mesylate (0.83 mg. per ml.) in an attempt to restore erectile function. Of the patients 52 completed the protocol and all achieved transient functional penile erections after administration of the drug. Of the 52 responders 71 per cent currently practice self-injection as a method to restore erectile function. Sustained erections that required irrigation of the cavernous bodies with alpha-adrenergic agents developed in 4 patients and 1 suffered localized intracorporeal induration. If the long-term followup shows that complications remain relatively minor, undoubtedly vasoactive intracavernous pharmacotherapy will have a major role in the restoration of erectile function in the motivated man with spinal cord injury. However, in view of the unknown long-term effects and potential dangers of this approach it is important that patients adhere to a strict drug injection protocol under the supervision of qualified urologists who are familiar with the potential risks and complications.
D000328:Adult; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000627:therapeutic use*; D010410:Penile Erection / Q000187:drug effects*; D010646:Phentolamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012646:Self Administration; D013119:Spinal Cord Injuries / Q000150:complications*; D013997:Time Factors
D004338:Drug Combinations; D010208:Papaverine; D010646:Phentolamine